The distribution of tissue factor pathway inhibitor (TFPI) consisting of free, lipoprotein-bound and endothelial anchoring forms, was studied in 156 patients with coronary artery disease (average age 61.2±9.1: range 32 to 78 years-old) by heparin infusion (50 IU/kg), and compared with the pre-heparin TFPI levels of 229 healthy subjects (average age 59.6±9.4 : range 41 to 80 years-old). In the pre-heparin state, the patients had lower free TFPI and lower high-density lipoprotein cholesterol (HDL.c) levels than those of the healthy subjects with equivalent lipoprotein-bound forms (free TFPI; 15.9±6.5 vs. 19.2± 8.1 ng/ml). In a partial correlation analysis, the free TFPI levels were shown to be inversely correlated with the HDL.c concentrations in both the patients (r=.-454:P<.001) and the healthy subjects (r=.-136:P<.05). In the post-heparin state, the patients generally showed free form levels less than 10%, lipoprotein-bound form levels at 30% and endothelial TFPI at 60%. The patients were divided into four categories by their low density lipoprotein cholesterol (LDL.c:130 mg/dl) and HDL.c (40 mg/dl) levels to specify their coronary risks.
INTRODUCTION
Tissue factor pathway inhibitor (TFPI) plays an important role in the anti-thrombotic properties of vessel walls by inhibiting extrinsic coagulation processes (1-2). Intravascular TFPI consists of three major pools except in platelets (3), i.e., the free form without carrier, lipoprotein-bound form (4) and endothelial anchoring form (5). An exogenous administration of recombinant TFPI to experimental animals prevents thrombosis (6) while increased TFPI levels have been observed in patients with acute myocardial infarction (7).
Although the alteration of serum lipids by cholesterol lowering therapy influences lipoprotein-bound TFPI profiles (8-11), little is known about the clinical implications of the TFPI level and its regulation in relation to lipid risk profiles.
In the present study, we compared TFPI subfractions in pre-heparin plasmas of normal healthy subjects and patients with coronary artery disease (CAD). Significant negative correlations were observed between the free TFPI and high density lipoprotein cholesterol (HDL.c) concentrations in both of these groups. Accordingly, we studied the TFPI distribution including endothelial TFPI levels in CAD patients divided according to their different phenotypes of dyslipidemias, especially hypercholesterolemia (high low density lipoprotein cholesterol: LDL.c) and low HDL cholesterolemia to evaluate the patients' coronary risks. Although lipoprotein-bound TFPI constitutes the major part of circulating TFPI, endothelial TFPI released by heparin is physiologically the most important form.
Because the amount of endothelial TFPI is the still greater than that of lipoprotein-bound form in vessels and mediates the major antithrombotic activity as free form (12-13).
Endothelial TFPI is believed to bind to heparan sulfate on the cell surface, as does lipoprotein lipase (LPL) (14), which regulates the LDL and HDL fractions by hydrolyzing triglyceride-rich lipoproteins (TGRL) and by producing LDL particles or a surface coat of Figure 1 shows a scatter gram of the LDL.c and HDL.c levels of the healthy subjects and CAD patients. The HDL.c levels of the patients were clearly shifted to the lower range characterizing lipid profiles of patients at risk for atherosclerosis ; 80 patients (51%) had HDL cholesterol levels in the range less than 1.03mmmol/L (40 mg/dl). The CAD patients had significantly lower serum lipids and apolipoprotein levels compared to those of the control subjects, except for the apo C-II levels (Table 1) . However, the apo A-II level divided by HDL.c was higher in the patients group than in the healthy subjects, indicating relatively increased apo A-II rich HDL particles in the CAD patients.
RESULTS

Comparison of serum lipid, apolipoprotein and TFPI levels in control subjects and patients
Both the free and total TFPI concentrations were significantly lower in the patients than in the control subjects. The lipoprotein-bound TFPI concentrations were not significantly different between the patients and control subjects. The free (TFPI) / total (TFPI) ratios and Lp-bound (TFPI) / total (TFPI) ratios showed that the TFPI in the control group was about one-fourth (25%) the free form and 75% the lipoprotein-bound form. The TFPI of the patients was about one-fifth (20%) the free form and 80% the lipoprotein-bound form.
Partial correlation coefficients in control subjects and patients
The free TFPI levels were inversely correlated with the HDL.c levels (Table 2) in both the healthy subjects (r=-.1358; P<.001: Fig. 2a ) and the CAD patients (r=-.4540; P<.001: negative correlation of free TFPI with HDL.c, the free TFPI concentration was positively correlated with the apo A-II level in both groups, more so in the patients. Although the circulating free TFPI was related to apo A-II rather than apo A-I in both the patients and the control subjects, the patients who had low HDL.c levels had a stronger correlation between free TFPI and apo A lipoproteins (apo A-I and apo A-II). In only the control group, free TFPI was correlated with the triglyceride level (r=.254; P<.001) and LDL.c level (r=.1669; P<.01).
The lipoprotein-bound TFPI level was found in LDL fraction as the major part in the control subjects (r=.4587; P<.001) and the patients (r=.4623;<.001). In the control group, the HDL fraction (r=.3152;P<.001) significantly contributed to the binding of lipoprotein-bound TFPI. In the patients, in contrast, an explanatory linkage of lipoprotein-bound TFPI and the HDL fraction was not observed.
Different forms of TFPI associated with dyslipidemic profiles
The patients were divided by their LDL.c and HDL.c levels into four categories ( Table 3) .
The low HDL.c groups (b and c) had higher BMI and lesser alcohol consumption values than those of the patients without low HDL.c (a and d). There was no significant difference in smoking status among the groups. LDL.c and HDL.c contributed to the significant differences of TC, apo A-I and apo B between the patients with low HDL.c (b and c) and high LDL.c (c and d) without any secondary interaction. Although the apo A-II levels were lower in the high LDL.c groups, the apo A-II / HDL.c ratio was significantly elevated in the low HDL.c groups. Apo C-II levels were also higher in the low HDL.c patients than in the patients without low HDL.c.
The heparin infusion (50 IU/kg) caused marked increases in the circulating free TFPI, from 7.7-to 11.1-fold and LPL concentrations from 12-to 16-fold in the pre-heparin plasma ( 
